Nordmark Arzneimittel Gmbh

Basf Aktiengesellschaft

Nordmark Arzneimittel Gmbh & Co. Kg

Other

Knoll Aktiengesellschaft

Nordmark Arzeimittel Gmbh and Co, Kg

Nordmark Areneimittel Gmbh & Co. Kg

Nordmark Pharma Gmbh

Thomas Moest

Claus H Pich

Manfred Kurfürst

Christian Rämsch

Ludwig Matz

Thomas Schräder

Walter Doleschal

Helmut Fricke

Ernst Flaig

Uwe Loeffler

Hans Waiblinger

The invention is a method for reducing the viral and microbial content of biological extracts which contain solids. The method comprises the steps of, (1), providing a biological extract which contains solids that comprise a biologically active substance, selected from enzymes, proteins and peptides, or a mixture of such substances; and (2) subjecting the biological extract to a high-pressure treatment; wherein the biological activity of the biological extract after the high-pressure treatment is at least 50% of the biological activity of the biological extract before the high-pressure treatment.

Method for reducing the viral and microbial load of biological extracts containing solids

In order to prevent impairment of the pharmacological effect of pancreatine through added auxiliary substances or binding agents a pancreatine pellet consists exclusively of pancreatine.

Pancreatine pellets and method of producing same

In order to avoid compromising the pharmacological effect of pancreatin caused by the addition of auxiliary materials or binding agents, a pancreatin pellet having a 100% pancreatin content consists exclusively of pancreatin with a residual moisture content of less than 3% by weight, preferably less than 1% by weight or less than 0.5% by weight.

Method for producing pancreatin pellets

The invention relates to a method for producing pancreatin with reduced viral and microbial contamination, comprising the steps of (a) providing the pancreatin in solid form with a residual moisture of 0.5 weight % or less, down to almost zero, based on the pancreatin provided; (b) subjecting the pancreatin provided in step (a) to a heat treatment at a temperature of 84&#xb0; C., preferably 80&#xb0; C. and below; wherein, the biological activity of the pancreatin obtained in step (b) corresponds to at least 50% of the biological activity of the pancreatin provided in step (a); and the viral infectiousness of the pancreatin obtained in step (b) has been reduced by a factor of more than 1 login comparison with the viral infectiousness of the pancreatin provided in step (a), as well as a pancreatin produced according to this method and its use for producing a medicine or a nutritional supplement.

Pancreatin and method for reducing the viral and microbial contamination of pancreatin

A dosing spoon for microtablets is described for which the lower part ( ) of the spoon consists of an even polygone which possesses a border ( ) on all sides with exception of one side and whereby the polygone has a number of individual recesses ( ) which are formed in such a way that an individual microtablet fits in each individual recess.

Dosing spoon for micro-tablets

A process for producing pellets which are markedly spherical and have a particle size in the range from 0.1 to 4 mm and an apparent density above 0.5 g/cm.sup.3, and which are composed of 90-100% by weight of an ephedrine derivative and 0-10% by weight of a pharmaceutical aid, entails suspending ephedrine derivative powder with an average particle size of from 0.5 to 50 .mu.m at 0.degree.-90.degree. C. with stirring in a water-immiscible non solvent with a boiling point in the range from 60.degree. to 160.degree. C., adding 5-60% by weight, based on the ephedrine derivative, of an agglomerating liquid while continuing stirring, and, if there has been previous heating, cooling to from -5 to 25.degree. C. at 5-40K per hour, with the stirring speed being adjusted after the agglomeration of the powder particles to a value which is necessary for the required average particle size, and removing and drying the resulting pellets. A drug which contains the active ingredient in the form of such pellets, with or without slowing of release, is also described.

Production of pellets composed of an ephedrine derivative

A solid drug form containing not less than 90% by weight verapamil is produced by granulating at from 30.degree. to 55.degree. C. with a little water, drying and, where appropriate, conventional tableting or by pelleting, in which case the granules obtained as described are, after cooling, moistened once again and compacted in a granulating mixer at from 30.degree. to 55.degree. C. and are dried.

Solid drug form with a high verapamil content

A biconvex tablet whose height and diameter are approximately equal and are from 1.5 to 4 mm and which, besides conventional pharmaceutical auxiliaries, contains an antacid as active substance is described.

Antacid microtablets

A solid pharmaceutical sustained-release form, consisting of a core containing the active compound as well as conventional pharmaceutical auxiliaries, a coat which delays the release of the active compound and an antiadhesive outer layer, wherein the coat consists of a physiologically acceptable fat-like or wax-like hydrophobic layer which melts in the range from 30.degree. to 120.degree. C. and contains, in addition to conventional pharmaceutical auxiliaries, one or more water-insoluble polymers, and a process for its preparation.

Solid pharmaceutical sustained-release form

A process for the manufacture of pellets which are composed of xanthine derivatives and are predominantly spherical, have a particle size in the range of 0.3 to 4 mm and have a bulk density above 0.5 g/cm.sup.3 by reacting the appropriate xanthine derivative with water or a water/alcohol mixture, entails anhydrous powdered xanthine derivative with an average particle size of from 20 to 200 .mu.m being suspended by stirring at from 40.degree. to 70.degree. C. in a nonsolvent which is immiscible with water and has a boiling point in the range from 60.degree. to 160.degree. C., then adding from 10 to 40% by weight, based on the anhydrous xanthine derivative, of water or a water/alcohol mixture and subsequently allowing to cool to room temperature at from 5.degree. to 20.degree. C. per hour, it being possible to reduce the stirring speed after agglomeration to about 1/3 to 2/3 of the original, and the pellets being separated from the liquid and dried, the pellets being used, possibly with a delayed release coating, as active compound in a drug.

Manufacture of pellets of xanthine derivatives

Cylindrical microtablets which have a convex upper face and a convex lower face and whose cylinder diameter and height independently of one another are each from 1.0 to 2.5 mm and the ratio of the said diameter to said height is from 1:0.5 to 1:1.5, an a process for their preparation.

Cylindrical microtablets

In an apparatus for removing portions of identical materials (4) in the form of pieces by means of a sliding part which is encased in a dispensing container and operated from the outside and whose dispensing sector (5) is filled from inside the container and can be emptied outward, the sliding part is in the form of a tube section (1) which has one or more dispensing sectors (5) and is fed through an outer shell (3) and a stripper (2) located adjacent to the ejection orifice (9) and assigned to the dispensing sectors (5).

Apparatus for metering materials in the form of pieces

Cylindrical microtablets which have a convex upper face and a convex lower face and whose cylinder diameter and height independently of one another are each from 1.0 to 2.5 mm and the ratio of the said diameter to said height is from 1:0.5 to 1:1.5, and a process for their preparation.

A process for the preparation of solid pharmaceutical products, wherein, in a first step, spherical single crystals of a pharmaceutical active compound or assistant are prepared by agitating a saturated aqueous, organic or organic-aqueous solution in high speed stirred crystallizers or draft-tube crystallizers at 50-500 revolutions per minute and seeding the solution with finely ground seed crystals of particle size less than 100 .mu.m, while ensuring that at the time of addition of the seed crystals and during the growth thereof the solution is at all times only minimally supersaturated, this being achieved by slow cooling at a rate of not more than 50 K/h or corresponding slow evaporation of the solution, and in a second step the resulting spherical single crystals with diameters of 0.1-3 mm, preferably 0.5-2 mm, are separated from the solution, dried at 40.degree.-200.degree. C., compounded, where appropriate, with suitable pharmaceutical assistants or, if the single crystals serve as assistants, with suitable pharmaceutical active compounds, and then converted to solid pharmaceutical products by coating, tableting or filling into hard gelatin capsules.

Process for the preparation of solid pharmaceutical products

A stringently sodium-restricted dietetic salt consisting of a mixture of from 60 to 85% by weight of potassium chloride, from 10 to 30% by weight of potassium adipate, from 2 to 5% by weight of potassium tartrate, from 0.5 to 2% by weight of potassium glutamate, from 0.5 to 2% by weight of adipic acid and a total of from 0.004 to 0.06% by weight of potassium inosate and/or potassium guanylate, and the preparation of the salt in a fluidized bed apparatus.

Growing community of inventors

Moorrege, Germany

Thomas Moest